Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

TUMORGAN

Financiado

Cerrado

Exploring the tumor as a communicating organ

The failure to bring about major advances in cancer care over the past decades points to the need for a revolution in our view of cancer as a disease caused by a lack of growth control in malignant cells. We propose that a tumor s... ver más

28/02/2018

1M€

Presupuesto del proyecto: 1M€

Líder del proyecto

MAX IV Laboratory, Lund University No se ha especificado una descripción o un objeto social para esta compañía.

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2018-02-28 No tenemos la información de la convocatoria

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

1.50M€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

MERIC Mechanisms of Evasive Resistance in Cancer 11M€ Cerrado

GNS_cells Biochemical and functional studies of lineage specific trans... 200K€ Cerrado

SAF2014-55944-R IDENTIFICACION DE LOS MECANISMOS MOLECULARES QUE REGULAN LA... 145K€ Cerrado

DualRP Exploring cell interactions in the tumor microenvironment wi... 1M€ Cerrado

SAF2014-57791-REDC BIOLOGIA DEL CANCER 45K€ Cerrado

ReTuBi Towards outstanding research and training in tumour biology... 1,000K€ Cerrado

Líder del proyecto

MAX IV Laboratory, Lund University No se ha especificado una descripción o un objeto social para esta compañía.

Presupuesto del proyecto 1M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The failure to bring about major advances in cancer care over the past decades points to the need for a revolution in our view of cancer as a disease caused by a lack of growth control in malignant cells. We propose that a tumor should be considered a communicating organ made of multiple cell types that collectively evolve into a clinically manifested and deadly disease. With this proposition follows that targeting of communication within tumors to attenuate the support from the stroma is the only viable strategy to achieve long term therapeutic benefit. Our research addresses the need to study the cellular context of cancer with a higher resolution. The general aim of the proposed work is to identify subsets of different cell types within the tumor stroma that hold utility as therapeutic targets and biomarkers. The work will be performed through a set of experiments bridging basic biology, pre-clinical studies and molecular oncology. The specific aims are: 1) Identification of cellular subsets of the tumor vasculature 2) Investigation of the therapeutic utility of cellular subsets of the tumor vasculature 3) Exploration of the potential of cellular subsets of the tumor vasculature as biomarkers The aims of the study will be pursued through a series of methodological refinements. Firstly, identification of novel components of tumors will be achieved by the assembly of a mouse genetic tool box enabling isolation, lineage tracing and functional studies. Secondly, single cell transcriptome sequencing will be performed to identify cellular subsets using materials from both mouse and man. Thirdly, the utility as therapeutic targets of the new cellular subsets will be assessed using a live imaging approach. Fourthly, the clinical significance of the new cellular subsets will be investigated using exclusive patient materials. Taken together, the information provided by our studies will enable us to take cancer therapy into a new era of personalized medicine.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores